Iterum Therapeutics
1.64
0.04 (2.50%)
At close: Jan 15, 2025, 1:37 PM
undefined%
Bid 1.64
Market Cap 45.15M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.76
PE Ratio (ttm) -0.93
Forward PE n/a
Analyst Buy
Ask 1.65
Volume 172,577
Avg. Volume (20D) 3,077,850
Open 1.63
Previous Close 1.60
Day's Range 1.60 - 1.70
52-Week Range 0.81 - 3.02
Beta undefined

About ITRM

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company ...

Industry Biotechnology
Sector Healthcare
IPO Date May 25, 2018
Employees 14
Stock Exchange NASDAQ
Ticker Symbol ITRM

Analyst Forecast

According to 1 analyst ratings, the average rating for ITRM stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 204.75% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
2 months ago · Source
+60.68%
Iterum Therapeutics shares are trading higher afte... Unlock content with Pro Subscription
5 months ago · Source
+11.32%
Iterum Therapeutics shares are trading higher after the company announced it will receive gross proceeds of $7.4M from the expiration and results of its rights offering.